CORVUS PHARMACEUTICALS INC (CRVS) Stock Analyst Earnings Estimates
NASDAQ:CRVS - Nasdaq - US2210151005 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 874.85% | N/A 187.50% | N/A 78.03% | N/A 63.38% | N/A 58.98% | N/A 41.66% | |||||||||||
| EBITDA YoY % growth | -160K | -13.62M -8,412.50% | -36.39M -167.18% | -55.68M -53.01% | -48.37M 13.13% | -48.11M 0.54% | -43.13M 10.35% | -38.17M 11.50% | -32.2M 15.64% | -23.256M 27.78% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -160K | -13.77M -8,506.25% | -36.98M -168.55% | -56.52M -52.84% | -49.22M 12.92% | -48.85M 0.75% | -43.76M 10.42% | -38.63M 11.72% | -32.57M 15.69% | -23.407M 28.13% | N/A -19.02% | N/A -31.30% | N/A -34.00% | N/A -8.24% | N/A 71.36% | N/A 325.52% | N/A 130.09% | N/A 118.31% | N/A 48.12% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -6.88 | -2.72 60.47% | -1.75 35.66% | -1.59 9.14% | -1.46 8.18% | -1.06 27.40% | -0.89 16.04% | -0.57 35.96% | N/A -65.48% | N/A 45.69% | N/A -32.90% | N/A 17.23% | N/A 87.78% | N/A 755.56% | N/A 89.08% | N/A 91.23% | N/A 12.08% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.12 12.94% | -0.13 -4.55% | -0.12 -211.10% | -0.13 77.67% | -0.14 -14.64% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.088M -43.13% | -8.738M -39.74% | -9.146M -54.10% | -9.662M -33.18% | -10.118M -25.10% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.60 -400.00% | -0.12 | -0.48 | -404.49% |
| Q2 2024 Q2Q % growth | -0.04 71.43% | -0.12 | 0.08 | 65.90% |
| Q1 2024 Q2Q % growth | -0.12 29.41% | -0.14 | 0.02 | 12.85% |
| Q4 2023 Q2Q % growth | -0.14 33.33% | -0.12 | -0.02 | -15.34% |
| Q3 2023 Q2Q % growth | -0.12 62.50% | -0.12 | 0.00 | 3.57% |
| Q2 2023 Q2Q % growth | -0.14 22.22% | -0.14 | 0.00 | 1.43% |
| Q1 2023 Q2Q % growth | -0.17 5.56% | -0.16 | -0.01 | -6.16% |
| Q4 2022 Q2Q % growth | -0.21 -5.00% | -0.24 | 0.03 | 10.87% |
| Q3 2022 Q2Q % growth | -0.32 -33.33% | -0.16 | -0.16 | -100.25% |
| Q2 2022 Q2Q % growth | -0.18 35.71% | -0.18 | 0.00 | 0.11% |
| Q1 2022 Q2Q % growth | -0.18 47.06% | -0.16 | -0.02 | -15.09% |
| Q4 2021 Q2Q % growth | -0.20 39.39% | -0.19 | -0.01 | -4.58% |
| Q3 2021 Q2Q % growth | -0.24 27.27% | -0.26 | 0.02 | 8.33% |
| Q2 2021 Q2Q % growth | -0.28 22.22% | -0.32 | 0.04 | 13.31% |
| Q1 2021 Q2Q % growth | -0.34 22.73% | -0.32 | -0.02 | -7.53% |
| Q4 2020 Q2Q % growth | -0.33 13.16% | -0.33 | 0.00 | -0.32% |
| Q3 2020 Q2Q % growth | -0.33 10.81% | -0.24 | -0.09 | -34.80% |
| Q2 2020 Q2Q % growth | -0.36 18.18% | -0.28 | -0.08 | -27.88% |
| Q1 2020 Q2Q % growth | -0.44 -10.00% | -0.41 | -0.03 | -8.28% |
| Q4 2019 Q2Q % growth | -0.38 | -0.34 | -0.04 | -13.41% |
| Q3 2019 Q2Q % growth | -0.37 | -0.42 | 0.05 | 12.59% |
| Q2 2019 Q2Q % growth | -0.44 | -0.44 | 0.00 | 0.38% |
| Q1 2019 Q2Q % growth | -0.40 | -0.41 | 0.01 | 1.96% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 10.15% | 0% | -133.13% |
| Revenue | N/A | N/A | N/A | N/A |